睿知中国医院研究地图
候选清单

正在招募肺癌不分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC

ClinicalTrials.gov 上登记的一项肺癌开放试验,由北京协和医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方北京协和医院Peking Union Medical College Hospital北京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07452003,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 9

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(9 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically confirmed non-small cell lung cancer (NSCLC).

    入选标准第 4 条

  3. TNM stage IIB to IIIB disease, assessed by surgeons as resectable or potentially resectable.

    入选标准第 7 条

  4. Pregnant women (positive pregnancy test prior to treatment) or breastfeeding women.

    排除标准第 5 条

    Major surgery (excluding biopsy) within 4 weeks prior to the first dose of study treatment, or incomplete wound healing from prior surgery.

    排除标准第 7 条

    Unresolved toxicities > grade 1 from any prior therapy or procedure (CTCAE version 5.0), except for alopecia, anemia, or hypothyroidism.

    排除标准第 25 条

  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

    入选标准第 8 条

    ECOG performance status >1.

    排除标准第 2 条

  6. Presence of actionable driver gene alterations with available targeted therapies, including but not limited to EGFR mutations, ALK fusions, ROS1 fusions, RET, NTRK, BRAF V600E mutations, or MET exon 14 skipping mutations.

    排除标准第 4 条

  7. At least one measurable lesion according to RECIST version 1.1 (measurable lesion defined as a longest diameter ≥10 mm on spiral CT scan, or lymph node with a short axis ≥15 mm).

    入选标准第 5 条

  8. Known history of human immunodeficiency virus (HIV) infection.

    排除标准第 22 条

    Concomitant malignancies or history of other malignancies within the past 5 years, except for adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the breast or cervix, treated superficial bladder cancer, or prostate adenocarcinoma treated surgically with prostate-specific antigen (PSA) within normal limits.

    排除标准第 27 条

  9. Women of childbearing potential must agree to remain abstinent (avoid heterosexual intercourse) or use highly effective contraception with a failure rate <1% per year during study treatment and for at least 6 months after the last dose.

    入选标准第 13 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07452003,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Patients are eligible for enrollment in this study only if they meet all of the following inclusion criteria and none of the exclusion criteria:
  2. The subject voluntarily participates in the study, provides written informed consent, demonstrates good compliance, and is willing to cooperate with study procedures and follow-up.
  3. Age ≥18 years at the time of signing the informed consent form; sex not restricted.
  4. Histologically confirmed non-small cell lung cancer (NSCLC).
  5. At least one measurable lesion according to RECIST version 1.1 (measurable lesion defined as a longest diameter ≥10 mm on spiral CT scan, or lymph node with a short axis ≥15 mm).
  6. No prior systemic therapy or local treatment for NSCLC.
  7. TNM stage IIB to IIIB disease, assessed by surgeons as resectable or potentially resectable.
  8. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  9. Pulmonary function within normal limits.
  10. Adequate hematologic and organ function, based on laboratory tests obtained within 14 days prior to initiation of study treatment (unless otherwise specified):
  11. Hematology (no blood transfusion, G-CSF, or corrective medications within 14 days prior to screening):
  12. Renal function:
  13. Women of childbearing potential must agree to remain abstinent (avoid heterosexual intercourse) or use highly effective contraception with a failure rate <1% per year during study treatment and for at least 6 months after the last dose.
  14. Women are considered of childbearing potential if they are menstruating, not postmenopausal (defined as ≥12 consecutive months of amenorrhea without other causes), and have not undergone sterilization (bilateral oophorectomy and/or hysterectomy).
  15. Male participants must agree to remain abstinent (avoid heterosexual intercourse) or use effective contraception and must agree not to donate sperm, as defined below:

排除标准:Exclusion Criteria:

  1. Prior exposure to any immunotherapy.
  2. ECOG performance status >1.
  3. Evidence of distant metastasis or intrathoracic metastatic disease.
  4. Presence of actionable driver gene alterations with available targeted therapies, including but not limited to EGFR mutations, ALK fusions, ROS1 fusions, RET, NTRK, BRAF V600E mutations, or MET exon 14 skipping mutations.
  5. Pregnant women (positive pregnancy test prior to treatment) or breastfeeding women.
  6. Known hypersensitivity or intolerance to recombinant humanized PD-1 monoclonal antibodies or any of their components (or excipients).
  7. Major surgery (excluding biopsy) within 4 weeks prior to the first dose of study treatment, or incomplete wound healing from prior surgery.
  8. Clinically significant cardiovascular or cerebrovascular disease, including but not limited to:
  9. Acute myocardial infarction within 6 months prior to enrollment
  10. Severe or unstable angina
  11. Cerebrovascular accident or transient ischemic attack
  12. Congestive heart failure (New York Heart Association class ≥II)
  13. Arrhythmias requiring antiarrhythmic treatment (except beta-blockers or digoxin)
  14. QTc interval >480 ms on repeated ECG measurements
  15. Hepatic or renal insufficiency, including conditions such as jaundice, ascites, and/or:
  16. Persistent active infection of grade >2 according to CTCAE version 5.0.
  17. Active autoimmune disease or history of autoimmune disease within the past 2 years, or known/suspected autoimmune disease that may affect vital organ function or require systemic immunosuppressive therapy, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.
  18. Allowed conditions include type I diabetes mellitus, hypothyroidism requiring hormone replacement only, and skin diseases not requiring systemic treatment (e.g., vitiligo, psoriasis, alopecia), or conditions not expected to recur without external triggers.
  19. Replacement therapies (e.g., thyroxine, insulin, or physiological corticosteroid replacement for adrenal or pituitary insufficiency) are not considered systemic immunosuppressive treatment.
  20. Prior or planned solid organ transplantation or allogeneic bone marrow transplantation.
  21. Active tuberculosis (Mycobacterium tuberculosis) or other active infections.
  22. Known history of human immunodeficiency virus (HIV) infection.
  23. Severe non-healing wounds, ulcers, or fractures.
  24. History of substance abuse, or any medical, psychological, or social condition that may interfere with study participation, compromise compliance, or pose a safety risk.
  25. Unresolved toxicities > grade 1 from any prior therapy or procedure (CTCAE version 5.0), except for alopecia, anemia, or hypothyroidism.
  26. Objective evidence of severe pulmonary dysfunction, including history of severe pulmonary fibrosis, interstitial lung disease, pneumoconiosis, radiation pneumonitis, or drug-related pneumonitis.
  27. Concomitant malignancies or history of other malignancies within the past 5 years, except for adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the breast or cervix, treated superficial bladder cancer, or prostate adenocarcinoma treated surgically with prostate-specific antigen (PSA) within normal limits.
  28. Any condition that, in the investigator's judgment, makes the patient unsuitable for participation in this study.
  29. Concurrent participation in another clinical study.

引自 ClinicalTrials.gov, NCT07452003, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07452003,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07452003